Hepatology Research最新文献

筛选
英文 中文
Imaging-Based Surveillance of Gastroesophageal Varices in Fontan-Associated Liver Disease: Toward a Noninvasive Strategy. fontan相关性肝病胃食管静脉曲张影像学监测:一种无创策略
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-07-03 DOI: 10.1111/hepr.14239
Tadashi Namisaki, Akihiko Shibamoto, Kosuke Kaji, Hitoshi Yoshiji
{"title":"Imaging-Based Surveillance of Gastroesophageal Varices in Fontan-Associated Liver Disease: Toward a Noninvasive Strategy.","authors":"Tadashi Namisaki, Akihiko Shibamoto, Kosuke Kaji, Hitoshi Yoshiji","doi":"10.1111/hepr.14239","DOIUrl":"https://doi.org/10.1111/hepr.14239","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to ''Circulating Myostatin Levels as a Prognostic Biomarker in Patients With Acute Liver Failure and Late-Onset Hepatic Failure''. 致“循环肌生长抑制素水平作为急性肝衰竭和迟发性肝衰竭患者预后的生物标志物”的信。
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-07-03 DOI: 10.1111/hepr.14242
Yanyan Zhang, Juanjuan Zhang
{"title":"Letter to ''Circulating Myostatin Levels as a Prognostic Biomarker in Patients With Acute Liver Failure and Late-Onset Hepatic Failure''.","authors":"Yanyan Zhang, Juanjuan Zhang","doi":"10.1111/hepr.14242","DOIUrl":"https://doi.org/10.1111/hepr.14242","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of Possible Telomerase Reverse Transcriptase Promoter Mutation in Human Chemically Induced Liver Progenitors. 化学诱导的人肝祖细胞中端粒酶逆转录酶启动子可能突变的研究。
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-07-01 DOI: 10.1111/hepr.14240
Baglan Askeyev, Akihiko Soyama, Daisuke Miyamoto, Kayo Hasegawa, Hajime Matsushima, Takanobu Hara, Takashi Hamada, Kazushige Migita, Takuro Fujita, Hajime Imamura, Mampei Yamashita, Tomohiko Adachi, Susumu Eguchi
{"title":"Investigation of Possible Telomerase Reverse Transcriptase Promoter Mutation in Human Chemically Induced Liver Progenitors.","authors":"Baglan Askeyev, Akihiko Soyama, Daisuke Miyamoto, Kayo Hasegawa, Hajime Matsushima, Takanobu Hara, Takashi Hamada, Kazushige Migita, Takuro Fujita, Hajime Imamura, Mampei Yamashita, Tomohiko Adachi, Susumu Eguchi","doi":"10.1111/hepr.14240","DOIUrl":"https://doi.org/10.1111/hepr.14240","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to investigate the presence of telomerase reverse transcriptase (TERT) promoter mutations in human chemically induced liver progenitors (hCLiPs) and to evaluate their potential association with carcinogenesis.</p><p><strong>Methods: </strong>TERT promoter mutations were analyzed in 20 formalin-fixed, paraffin-embedded HCC samples, 19 liver cirrhosis (LC) samples, and five hCLiPs derived from cirrhotic liver tissue. Genomic DNA was extracted, and droplet digital PCR was performed to detect TERT promoter mutations (C228T and C250T).</p><p><strong>Results: </strong>No TERT promoter mutations were detected in hCLiPs or LC samples. In contrast, 11 of 20 (55%) HCC samples carried the C228T mutation, with mutant allele frequencies ranging from 2.7% to 28.0% (mean ± SD: 21.6 ± 11.05%). The C250T mutation was not identified in any sample.</p><p><strong>Conclusion: </strong>These findings show that hCLiPs reprogrammed using small molecules do not harbor TERT promoter mutations, supporting their genomic stability and potential safety for clinical applications.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extrahepatic Events in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake. 代谢功能障碍相关脂肪变性肝病患者的肝外事件及遗传和酒精摄入的影响
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-07-01 DOI: 10.1111/hepr.14233
Tomomi Kogiso, Yuri Ogasawara, Makiko Taniai, Katsutoshi Tokushige, Yousuke Nakai
{"title":"Extrahepatic Events in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake.","authors":"Tomomi Kogiso, Yuri Ogasawara, Makiko Taniai, Katsutoshi Tokushige, Yousuke Nakai","doi":"10.1111/hepr.14233","DOIUrl":"https://doi.org/10.1111/hepr.14233","url":null,"abstract":"<p><strong>Aims: </strong>The Delphi consensus established new criteria for steatotic liver disease (SLD), but the extrahepatic complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) remain unclear. In this study, we investigated the clinical course of MASLD patients compared to those with MASLD and increased alcohol intake (MetALD) and alcohol-associated liver disease (ALD).</p><p><strong>Methods: </strong>A total of 1150 Asian patients with SLD were enrolled and categorized into the MASLD (n = 803), MetALD (n = 81), and ALD (n = 266) groups. The incidence levels of extrahepatic malignancies and cardiovascular disease (CVD) events were compared among the three groups. Genetic alterations in PNPLA3, HSD17B13, GCKR, and GDF15 were analyzed in 201 MASLD cases.</p><p><strong>Results: </strong>MASLD patients were significantly younger (MASLD, MetALD, ALD; 53, 65, and 62 years), had a lower proportion of males (49.3%, 82.7%, and 86.8%), and had a higher BMI (26.7, 24.1, and 22.6 kg/m<sup>2</sup>) than MetALD and ALD patients. During a median follow-up of 10.6 years, the proportions of patients who developed extrahepatic malignancies were 7.2%, 9.9%, and 5.6%, and those who experienced CVD events were 5.7%, 3.7%, and 4.1% in the MASLD, MetALD, and ALD groups, respectively. However, Cox proportional hazards analysis revealed no significant difference in the risk of extrahepatic complications among the groups after adjusting for baseline characteristics. A single nucleotide polymorphism in PNPLA3 was associated with the development of CVD events in MASLD patients.</p><p><strong>Conclusions: </strong>Extrahepatic events were observed at similar rates among patients with SLD after adjusting for confounding factors. However, overall mortality and the risk of HCC were significantly higher in the MetALD and ALD groups.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing Gene Mutation Analysis Through Post-Ablation Liver Tumor Biopsy Specimens. 通过消融后肝肿瘤活检标本推进基因突变分析。
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-07-01 DOI: 10.1111/hepr.14237
Tasuku Nakabori, Yoji Kukita, Hidetoshi Satomi, Kaori Mukai, Minoru Shigekawa, Shigenori Nagata, Kazuyoshi Ohkawa
{"title":"Advancing Gene Mutation Analysis Through Post-Ablation Liver Tumor Biopsy Specimens.","authors":"Tasuku Nakabori, Yoji Kukita, Hidetoshi Satomi, Kaori Mukai, Minoru Shigekawa, Shigenori Nagata, Kazuyoshi Ohkawa","doi":"10.1111/hepr.14237","DOIUrl":"https://doi.org/10.1111/hepr.14237","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Glucose Intolerance a Precursor of Cachexia in Patients With Liver Cirrhosis? 葡萄糖耐受不良是肝硬化患者恶病质的前兆吗?
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-06-29 DOI: 10.1111/hepr.14235
Tsutomu Nishida, Satoru Okabe, Akira Doi, Kengo Matsumoto
{"title":"Is Glucose Intolerance a Precursor of Cachexia in Patients With Liver Cirrhosis?","authors":"Tsutomu Nishida, Satoru Okabe, Akira Doi, Kengo Matsumoto","doi":"10.1111/hepr.14235","DOIUrl":"https://doi.org/10.1111/hepr.14235","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum Alpha-Fetoprotein/Hepatocyte Growth Factor Ratio as a Novel Biomarker Predicting the Prognosis of Acute Alcoholic Hepatitis: Need of Validation and Dynamic Assessment to Establish Utility. 血清甲胎蛋白/肝细胞生长因子比率作为预测急性酒精性肝炎预后的新生物标志物:需要验证和动态评估以建立实用性。
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-06-24 DOI: 10.1111/hepr.14234
Ajay Kumar Mishra
{"title":"Serum Alpha-Fetoprotein/Hepatocyte Growth Factor Ratio as a Novel Biomarker Predicting the Prognosis of Acute Alcoholic Hepatitis: Need of Validation and Dynamic Assessment to Establish Utility.","authors":"Ajay Kumar Mishra","doi":"10.1111/hepr.14234","DOIUrl":"https://doi.org/10.1111/hepr.14234","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond Biochemical Response: Rethinking Risk Stratification and Endpoint Hierarchy in PBC. 超越生化反应:重新思考PBC的风险分层和终点层次。
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-06-20 DOI: 10.1111/hepr.14230
Yadi Li, Zheng Wei, Xinmin Deng
{"title":"Beyond Biochemical Response: Rethinking Risk Stratification and Endpoint Hierarchy in PBC.","authors":"Yadi Li, Zheng Wei, Xinmin Deng","doi":"10.1111/hepr.14230","DOIUrl":"10.1111/hepr.14230","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes. 肝硬化心肌病:患病率和对肝硬化结局的临床影响。
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-06-19 DOI: 10.1111/hepr.14232
Takashi Kitagataya, Goki Suda, Takatsugu Tanaka, Shoichi Kitano, Naohiro Yasuura, Akimitsu Meno, Takashi Sasaki, Risako Kohya, Qingjie Fu, Shunichi Hosoda, Sonoe Yoshida, Osamu Maehara, Shunsuke Ohnishi, Masatsugu Ohara, Masato Nakai, Takuya Sho, Kosuke Nakamura, Suguru Ishizaka, Naoya Sakamoto
{"title":"Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes.","authors":"Takashi Kitagataya, Goki Suda, Takatsugu Tanaka, Shoichi Kitano, Naohiro Yasuura, Akimitsu Meno, Takashi Sasaki, Risako Kohya, Qingjie Fu, Shunichi Hosoda, Sonoe Yoshida, Osamu Maehara, Shunsuke Ohnishi, Masatsugu Ohara, Masato Nakai, Takuya Sho, Kosuke Nakamura, Suguru Ishizaka, Naoya Sakamoto","doi":"10.1111/hepr.14232","DOIUrl":"https://doi.org/10.1111/hepr.14232","url":null,"abstract":"<p><strong>Aim: </strong>Cirrhotic cardiomyopathy (CCM) is a significant complication of liver cirrhosis; however, its prevalence and impact in Asian populations remain unclear. The aim of this study was to assess the prevalence of CCM in Japanese patients with liver cirrhosis and to evaluate its impact on clinical outcomes.</p><p><strong>Methods: </strong>In this retrospective study, 80 patients with liver cirrhosis confirmed using transient elastography (liver stiffness ≥ 12.5 kPa) were included. Study was performed at Hokkaido University Hospital between January 2014 and April 2024. CCM was diagnosed using the 2019 Cirrhotic Cardiomyopathy Consortium criteria. Subsequently, patient characteristics, survival, and the incidences of decompensation and cardiovascular events were analyzed.</p><p><strong>Results: </strong>The prevalence of CCM was 46.3% (37/80), with 78.4% of patients with CCM showing isolated systolic dysfunction based on global longitudinal strain. Patients with CCM were significantly older, had lower serum ammonia and bilirubin levels, and had higher platelet counts. CCM was associated with a significantly higher incidence of decompensation events (hazard ratio 3.97, 95% confidence interval 1.64-9.61, p = 0.003) and was an independent risk factor for decompensation in the multivariate analysis (hazard ratio 3.24, 95% confidence interval 1.29-8.11, p = 0.012). Patients with and without CCM showed no significant differences in overall survival or cardiovascular events.</p><p><strong>Conclusions: </strong>CCM is prevalent among Japanese patients with liver cirrhosis and is associated with an increased risk of hepatic decompensation. These findings highlight the importance of cardiac evaluation in patients with cirrhosis and suggest that CCM should be considered in the management of liver cirrhosis to improve patient outcomes.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progressive Sarcopenia as a Prognostic Marker in the Era of Immunotherapy. 进行性肌肉减少症作为免疫治疗时代的预后标志。
IF 3.9 3区 医学
Hepatology Research Pub Date : 2025-06-19 DOI: 10.1111/hepr.14231
Takeshi Okamoto, Takashi Sasaki, Masato Ozaka, Naoki Sasahira
{"title":"Progressive Sarcopenia as a Prognostic Marker in the Era of Immunotherapy.","authors":"Takeshi Okamoto, Takashi Sasaki, Masato Ozaka, Naoki Sasahira","doi":"10.1111/hepr.14231","DOIUrl":"https://doi.org/10.1111/hepr.14231","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信